Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dr. Gian Luca Forni, Ente Ospedaliero Ospedali Galliera
ClinicalTrials.gov Identifier:
NCT00907283
First received: May 21, 2009
Last updated: September 9, 2013
Last verified: September 2013
  Purpose

This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations. The drug will be administered in the dosage of 15 mg/kg twice daily. The safety and tolerability of the drug will be evaluated by measuring hemochrome every seven days with leukocyte formula count.

At 3, 6 and 12 months from the start of treatment, a neurological evaluation will be performed using several specific evaluation scales (International Cooperative Ataxia Rating Scale (ICARS); Unified Parkinson's Disease Rating Scale (UPDRS); Burke-Fahn-Marsden (BFM)).

Every 6 months of treatment, a brain magnetic resonance image (MRI) aimed at measuring iron overload quantitatively, if possible.


Condition Intervention Phase
Neurodegenerative Disease
Iron Overload
Drug: Deferiprone
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)

Resource links provided by NLM:


Further study details as provided by Ente Ospedaliero Ospedali Galliera:

Primary Outcome Measures:
  • To evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations. [ Time Frame: 6 months + 6 months (plus one year extension) ] [ Designated as safety issue: Yes ]
    Safety:CBC including ANC will be monitored weekly.If the liver enzymes are greater than 2.5 fold the upper limit of normal, the drug will be withheld and the assessment repeated in 1 week. If the laboratory values continue to be over 2.5 times the upper limit of normal or if the neutrophil counts decrease to less than 1.5 x 109/L (1500 cells/µl) the Patient will be withdrawn from the study. Neutropenia/Agranulocytosis is confirmed as an Absolute Neutrophil Count being less than 1.5 x 109/L (1500 cells/µl) if counts on two consecutive days are both less than 1.5 x 109 (1500 cells/µl).


Estimated Enrollment: 20
Study Start Date: November 2008
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Deferiprone
    15 mg/Kg/twice for 1 year
    Other Names:
    • EU/1/99/108/002 Ferriprox 100 mg/ml Oral solution 250 ml a bottle,EMEA approved on 19th nov 2007
    • EU/1/99/108/003 Ferriprox 100 mg/ml Oral solution 500 ml a bottle,EMEA approved on 19th nov 2007
Detailed Description:

The time interval between Study Start Date and Study First Received was related to bureaucratic problems.

The treatment of systemic iron overload has in recent years improved notably since new drugs and new therapeutic combinations have become available for use. Conversely, therapies for the removal of regional iron overloads on the cerebral level have not been described in the literature.

As it is known, the symptoms resulting from a cerebral iron overload are strongly disabling, reducing the patient's autonomy. Considering that valid therapeutic alternatives of proven preventive and/or curative efficacy in these neurodegenerative diseases do not exist today, the use of lipophilic iron chelators must be considered as a possible therapeutic strategy worthy of deeper study.

Deferiprone is an oral active iron chelator, the use of which is authorized for the treatment of iron overload in patients affected by thalassemia major in conditions of "chelation not suitable for Desferal." In recent years, deferiprone has been applied extensively, demonstrating a good efficacy and tolerability profile.

Unlike deferoxamine, a hydrophilic drug, deferiprone presents chemical-physical characteristics (low molecular weight, favourable octanol:water partition coefficient, neutral charge) that guarantee drug good permeability of mitochondrial walls and the blood-brain barrier.

In a recent study deferiprone (commercial name Ferriprox) was used in 13 patients with Friedreich's ataxia (FA), also treated with idebenone (an experimental drug with an anti-oxidant action), compared with 9 patients affected by FA but treated only with Idebenone. The 9 patients who completed the 6 months of treatment with deferiprone were evaluated from a clinical point of view using the ICARS Scale (International Cooperative Ataxia Rating Score) before the start and after 1 and 6 months of therapy. They also performed a cerebral Magnetic Resonance Imaging before and after 1, 2, 4 and 6 months of treatment. The results were promising. In fact, after 6 months of therapy, a reduction in iron accumulation in specific cerebral areas involved in the pathogenesis of neurodegenerative disease was demonstrated. The patients also presented a significant clinical improvement confirmed by the ICARS score.

Therefore the use of deferiprone, despite the possible side effects (such as gastrointestinal disturbances, a temporary increase in transaminases, and especially agranulocytosis found in about 1% of patients treated with deferiprone), currently represents the only possibility for removing and/or preventing the accumulation of iron in the central nervous system, curing and/or avoiding the most severe and debilitating consequences of a disease for which another therapy does not exist.

The Centers that specialize in the treatment of iron accumulation have acquired significant experience in the use of new oral iron chelators over the last 10 years, which permits deferiprone to be used carefully and safely in the three cases at hand. We therefore propose the use of this drug for treating patients who show neurological symptoms that can be correlated with a cerebral iron overload shown through MRI and who have not benefited from other therapies.

  Eligibility

Ages Eligible for Study:   1 Year to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients over > 1 years of age who have neurological symptoms that can be correlated with cerebral-level iron overload as documented with MRI.This inclusion criteria has been amended by Amendment 6, 24 march 2011)
  • Patients who have given informed consent.

Exclusion criteria:

  • Inability to be subjected to MRI exam.
  • Renal insufficiency (creatinine > 1.5 mg/dl).
  • Neoplasias.
  • Patients with average levels of ALT > 300 and patients with variations of ALT or AST of 300% during the year prior to enrolling. (At least 4 measurements in 12 months).
  • Systemic cardiovascular, renal, hepatic etc., diseases that could counter-indicate the therapeutic options specified.
  • Known hypersensitivity to deferiprone.
  • Patient judged potentially unreliable and/or uncooperative with regard to study procedures.
  • Pregnancy and breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00907283

Locations
Italy
Neurological Pathology Department, Brotzu Hospital
Cagliari, Italy, 09134
Centre of Microcitemia and Congenital Anemias, Galliera Hospital
Genoa, Italy, 16128
Clinic of Neurology, University of Genoa
Genoa, Italy, 16132
Sponsors and Collaborators
Ente Ospedaliero Ospedali Galliera
Investigators
Principal Investigator: Gian Luca Forni, MD E.O. Ospedali Galliera. Centro della Microcitemia e delle Anemie Congenite -Ematology - Genoa Italy
  More Information

Additional Information:
Publications:
Abbruzzese G, Cossu G, Balocco M, Marchese R, Murgia D, Melis M, Galanello R, Barella S, Matta G, Ruffinengo U, Bonuccelli U, Forni GL. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation.Haematologica. 2011 Nov;96(11):1708-11. Epub 2011 Jul 26.

Responsible Party: Dr. Gian Luca Forni, MD, Ente Ospedaliero Ospedali Galliera
ClinicalTrials.gov Identifier: NCT00907283     History of Changes
Other Study ID Numbers: Deferiprone08, EUDRACT NUMBER 2008-005206-39
Study First Received: May 21, 2009
Last Updated: September 9, 2013
Health Authority: Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by Ente Ospedaliero Ospedali Galliera:
NBIA
Iron overload AND brain
Iron chelation AND neurodegeneration
Brain iron Overload
Neurodegeneration
Brain iron Accumulation

Additional relevant MeSH terms:
Nerve Degeneration
Iron Overload
Neurodegenerative Diseases
Neuroaxonal Dystrophies
Iron Metabolism Disorders
Pantothenate Kinase-Associated Neurodegeneration
Pathologic Processes
Metabolic Diseases
Nervous System Diseases
Brain Diseases
Central Nervous System Diseases
Basal Ganglia Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Deferiprone
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014